Exelixis
EXEL
#1636
Rank
A$16.22 B
Marketcap
$57.96
Share price
-1.44%
Change (1 day)
58.80%
Change (1 year)
Exelixis, Inc. is an American genomics-based drug discovery company and the producer of Cometriq, a treatment for medullary thyroid cancer.

Earnings for Exelixis (EXEL)

Earnings in 2024 (TTM): A$1.03 Billion

According to Exelixis's latest financial reports the company's current earnings are A$2.16 Billion. , an increase over its 2023 earnings that were of A$0.41 Billion. The earnings displayed on this page is the company's Pretax Income.

Earnings history for Exelixis from 2000 to 2024

Annual earnings

Year Earnings Change
2024 A$1.08 B164.69%
2023 A$0.41 B9.89%
2022 A$0.37 B-20.33%
2021 A$0.46 B124.82%
2020 A$0.20 B-67.14%
2019 A$0.63 B-11.94%
2018 A$0.72 B185.09%
2017 A$0.25 B-325.82%
2016 -A$0.12 Billion-58.12%
2015 -A$0.27 Billion-37.61%
2014 -A$0.43 Billion9.75%
2013 -A$0.39 Billion65.96%
2012 -A$0.24 Billion-291.63%
2011 A$0.12 B-195.59%
2010 -A$0.13 Billion-42.17%
2009 -A$0.23 Billion-18.98%
2008 -A$0.28 Billion-6.99%
2007 -A$0.3 Billion46.3%
2006 -A$0.21 Billion33.25%
2005 -A$0.16 Billion-30.92%
2004 -A$0.22 Billion44.29%
2003 -A$0.16 Billion12.86%
2002 -A$0.14 Billion22.79%
2001 -A$0.11 Billion60.14%
2000 -A$68.27 Million

Earnings for similar companies or competitors

Company Earnings Earnings differencediff. Country
A$6.99 B 544.70%๐Ÿ‡ฌ๐Ÿ‡ง UK
A$12.64 B 1,065.14%๐Ÿ‡ซ๐Ÿ‡ท France
A$33.77 B 3,011.17%๐Ÿ‡บ๐Ÿ‡ธ USA
-A$13.35 Billion-1,329.24%๐Ÿ‡บ๐Ÿ‡ธ USA
A$7.34 B 576.16%๐Ÿ‡บ๐Ÿ‡ธ USA
A$27.77 B 2,458.83%๐Ÿ‡บ๐Ÿ‡ธ USA
A$17.69 B 1,530.33%๐Ÿ‡บ๐Ÿ‡ธ USA
-A$71.37 Million-106.57%๐Ÿ‡บ๐Ÿ‡ธ USA
-A$46.26 Million-104.26%๐Ÿ‡บ๐Ÿ‡ธ USA